Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-EN Version v5-FR
Language English French
Date Updated 2021-10-02 2021-10-01
Drug Identification Number 00872296 00872296
Brand name TRAVASOL TRAVASOL
Common or Proper name TRAVASOL Amino acids (Blend C) injection TRAVASOL Amino acids (Blend C) injection
Company Name BAXTER CORPORATION BAXTER CORPORATION
Ingredients LEUCINE SERINE TYROSINE PROLINE ARGININE GLYCINE L-ALANINE TRYPTOPHAN THREONINE HISTIDINE VALINE ISOLEUCINE L-LYSINE METHIONINE PHENYLALANINE LEUCINE SERINE TYROSINE PROLINE ARGININE GLYCINE L-ALANINE TRYPTOPHAN THREONINE HISTIDINE VALINE ISOLEUCINE L-LYSINE METHIONINE PHENYLALANINE
Strength(s) 730MG 500MG 40MG 680MG 1.15G 1.03G 2.07G 180MG 420MG 480MG 580MG 600MG 580MG 400MG 560MG 730MG 500MG 40MG 680MG 1.15G 1.03G 2.07G 180MG 420MG 480MG 580MG 600MG 580MG 400MG 560MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 3000 mL (JB6583) 3000 mL (JB6583)
ATC code B05BA B05BA
ATC description I.V. SOLUTIONS I.V. SOLUTIONS
Reason for shortage Shortage of an active ingredient. Shortage of an active ingredient.
Anticipated start date 2021-09-07 2021-09-07
Actual start date 2021-09-07 2021-09-07
Estimated end date
Actual end date 2021-10-01 2021-10-01
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order. Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order.
Health Canada comments